Diagnostic Method for Early Pancreatic Cancer Detection
Topics in This Section
Dr. Anthony Yeung and his researchers at the Fox Chase Cancer Center have identified a method for early detection of pancreatic cancer development.
Pancreatic cancer is a leading cause of cancer deaths which is associated with very poor survival rates. Advances in imaging techniques have allowed clinicians to visualize pancreatic cysts, yet there are no consistent tools for staging these lesions. Fox Chase researchers have identified more than 500 proteins in pancreatic cyst fluid collected from patients. The protein composition of the fluid has been correlated with existing cyst cancer markers to yield a proteomic signature of developing pancreatic cancer.
The pancreatic cyst fluid proteome can be used as a diagnostic tool for the detection of pancreatic cancer. Current diagnostic methods which include examination of biopsied tissue for cancer markers require an invasive procedure to obtain the sample and yield limited information based on staining for few markers. Furthermore, pancreatic cysts have complex histopathologic features often changing during cyst development. Obtaining cystic fluid from a patient can be done via minimally invasive procedures but cytology studies on cystic fluid have very low sensitivity. With the proposed proteomic mass spectroscopy approach, small fluid samples can yield an informative profile of the cyst assaying hundreds of proteins at the same time. A panel of 12 biomarkers that appears to facilitate cyst fluid classification has been found. Since the approach only requires a very small sample, smaller cysts can be assayed contributing to earlier detection of pancreatic cancer markers. The technology has huge potential as a diagnostic tool because of the possibilities for a high throughput, low hands-on platform utilizing existing mass spectroscopy technology.
Early and easy detection of pancreatic cancer
Ke E, Patel B, Liu T, et al. "Proteomic Analyses of Pancreatic Cyst Fluids, " (2009), Pancreas; 38(2): e33-42
U.S. Patent pending
For licensing information, contactInna Khartchenko
Associate Director, Office of Corporate Alliances Fox Chase Cancer Center
610 Old York Road, Suite 400
Jenkintown, PA 19046